Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Check-CapCHEKZ 21 Buyback Yield % is 0.00 as of Jul. 29, 2026. GuruFocus rates CHEKZ with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 88 Medical Diagnostics & Research companies, Check-Cap ranks worse than 1136362.5% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Check-Cap's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHEKZ vs XWEL, NDRA, BIAF: Buyback Yield % Comparison
For the Diagnostics & Research subindustry, Check-Cap's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Check-Cap Buyback Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Check-Cap's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Check-Cap's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Check-Cap (CHEKZ) has a Buyback Yield % of 0.00 as of Jul. 29, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Check-Cap and its competitors. According to the industry distribution chart, Check-Cap ranks #999999 out of 88 companies in the Medical Diagnostics & Research industry.
Is Check-Cap's Buyback Yield % too high?
Check-Cap's current Buyback Yield % is 0.00. Based on the distribution chart, Check-Cap ranks #999999 out of 88 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Check-Cap has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Check-Cap's Buyback Yield % compare to XWEL and NDRA?
According to the Medical Diagnostics & Research industry distribution chart, Check-Cap ranks #999999 out of 88 companies for Buyback Yield %. This places Check-Cap in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Diagnostics & Research company?
A good Buyback Yield % depends on the Medical Diagnostics & Research industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Check-Cap and its competitors. Check-Cap's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Check-Cap stock overvalued right now?
Check-Cap (CHEKZ) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Check-Cap's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Check-Cap (CHEKZ), the current Buyback Yield % is 0.00 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but plans to market products in the United States, Europe, Israel and Japan.
21GF Score
Get the complete analysis for CHEKZ
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHEKZ has been successfully added to your 
